Calidi Biotherapeutics (CLDI) Research & Development (2022 - 2026)

Calidi Biotherapeutics has reported Research & Development for 5 years, with the latest figure at $2.6 million in Q2 2026.

• On a quarterly basis, Research & Development fell 1.35% year-over-year to $2.6 million in Q2 2026; TTM through Jun 2026 was $9.9 million, a 9.84% increase from a year earlier, with the FY2025 full-year figure at $9.7 million, up 9.68% from the prior year.
• Research & Development was $2.6 million for Q2 2026 at Calidi Biotherapeutics, up from $2.4 million in the prior quarter.
• The five-year high for Research & Development was $4.0 million in Q4 2023, with the low at $1.8 million in Q4 2024.
• Average Research & Development over 5 years is $2.6 million, with a median of $2.4 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Research & Development surged 74.9% in 2023, then sank 54.14% in 2024.
• Over 5 years, Research & Development stood at $2.3 million in 2022, then soared by 74.9% to $4.0 million in 2023, then tumbled by 54.14% to $1.8 million in 2024, then advanced by 29.92% to $2.4 million in 2025, then climbed by 8.48% to $2.6 million in 2026.
• The last three Research & Development figures came in at $2.6 million (Q2 2026), $2.4 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.